Tetrathiomolybdate

Phase 3Small molecule

UUniversity of Michigan Rogel Cancer Center

Tetrathiomolybdate is one of 266 small molecule programs targeting Colorectal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

265

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CarcinomaActive, not recruiting

Wilson DiseaseActive, not recruiting

Esophageal CarcinomaActive, not recruiting

Psoriasis VulgarisActive, not recruiting

Primary Biliary CirrhosisActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Wilson DiseasePhase 3

Active, not recruiting

Esophageal CarcinomaPhase 2

Active, not recruiting

Psoriasis VulgarisPhase 2

Active, not recruiting

Primary Biliary CirrhosisPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tetrathiomolybdate

UUniversity of Michigan Rogel Cancer Center

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

Lexiscan

Astellas

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Chantix

PPrism Pharmaceuticals

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Preclinical

—7

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 8

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 9

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 10

Recombinant Human Chorionic Gonadotropin

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2036

Phase 1/2Recruiting

Capecitabine

NCT06134375

Clinical

Trials by Indication[1]

Capecitabine1 trial

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Recruiting·—·Phase 1/2·NCT06134375·204 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis

Completed·UUniversity of Michigan·Phase 1/2·NCT00189176·23 enrolled

Hepatocellular Carcinoma1 trial

Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00006332

Esophageal Carcinoma1 trial

Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00176800·69 enrolled

Psoriasis Vulgaris1 trial

A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris

Completed·UUniversity of Michigan·Phase 2·NCT00113542·10 enrolled

6 more indications

Prostate Cancer1 trial

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00150995·19 enrolled

Wilson disease1 trial

Study of Tetrathiomolybdate in Patients With Wilson Disease

Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004339·90 enrolled

Non-Small Cell Lung Cancer1 trial

Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

Completed·UUniversity of Rochester·Phase 1·NCT01837329·26 enrolled

Colorectal Carcinoma1 trial

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00176774·24 enrolled

Breast Cancer1 trial

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00195091·16 enrolled

Primary Biliary Cirrhosis1 trial

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

Completed·GGeorge Brewer·Phase 3·NCT00805805·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Tetrathiomolybdate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tetrathiomolybdate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tetrathiomolybdate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Michigan Rogel Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Michigan Rogel Cancer Center

Tetrathiomolybdate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2036

Trials by Indication[1]

Capecitabine1 trial

Idiopathic Pulmonary Fibrosis1 trial

Hepatocellular Carcinoma1 trial

Esophageal Carcinoma1 trial

Psoriasis Vulgaris1 trial

Prostate Cancer1 trial

Wilson disease1 trial

Non-Small Cell Lung Cancer1 trial

Colorectal Carcinoma1 trial

Breast Cancer1 trial

Primary Biliary Cirrhosis1 trial

References

Drug Info

Quick Facts

Related News